We are analyzing https://link.springer.com/article/10.1007/s00262-003-0451-2.

Title:
Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA | Cancer Immunology, Immunotherapy
Description:
This study was conducted in prostate cancer patients in biochemical relapse after radical prostatectomy, to assess the feasibility, safety, and immunogenicity of therapeutic vaccination with autologous dendritic cells (DCs) pulsed with human recombinant prostate-specific antigen (PSA) (Dendritophage-rPSA). Twenty-four patients with histologically proven prostate carcinoma and an isolated postoperative rise of serum PSA (>1 ng/ml to 10 ng/ml) after radical prostatectomy were included. The patients received nine administrations of PSA-loaded DCs by combined intravenous, subcutaneous, and intradermal routes over 21 weeks. Postbaseline blood tests were performed at months 1, 3, 6, 9, and 12 (PSA levels), at months 6 and 12 (circulating prostate cancer cells), at month 6 (anti-PSA IgG and IgM antibodies), and at up to eight time points before, during, and after immunization (PSA-specific T cells). Circulating prostate cancer cells detected in six patients at baseline were undetectable at 6 months and remained undetectable at 12 months. Eleven patients had a postbaseline transient PSA decrease on one to three occasions, predominantly occurring at month 1 (7 patients) or month 3 (2 patients). Maximum PSA decrease ranged from 6% to 39%. PSA decrease on at least one occasion was more frequent in patients with low Gleason score (p=0.016) at prostatectomy and with positive skin tests at study baseline (p=0.04). PSA-specific T cells were detected ex vivo by ELISpot for IFN-γ in 7 patients before vaccination and in 11 patients after vaccination. Of the latter 11 patients, 5 had detectable T cells both before and during the vaccination period, 4 only during the vaccination period, while 2 patients could for technical reasons not be assessed prevaccination. No induction of anti-PSA IgG or IgM antibodies was detected. There were no serious adverse events or otherwise severe toxicities observed during the trial. Immunization with Dendritophage-rPSA was feasible and safe in this cohort of patients. An immune response specific for PSA could be detected in some patients. A notable effect was the disappearance of circulating prostate cells in all patients who were RT-PCR positive before vaccination.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

google, scholar, cas, pubmed, cancer, cells, article, prostate, patients, dendritic, psa, immunol, prostatectomy, antigen, vaccination, human, radical, cell, prostatespecific, clin, med, benoît, circulating, clinical, privacy, cookies, content, barrou, month, men, partin, walsh, tumor, paris, france, analysis, information, publish, search, immunology, immunotherapy, autologous, pulsed, salcedo, blood, months, detected, specific, access, principles,

Topics {✒️}

granulocyte/macrophage colony-stimulating factor tumor necrosis factor alpha month download article/chapter monocyte-derived dendritic cells dendritic cell-based immunotherapy prostate-specific membrane antigen olivier cussenot hormone-refractory prostate cancer circulating prostate cells assessing t-cell responses bcr-abl-positive leukemia human prostatic carcinoma circulating tumor cells hôpital la pitié-salpétrière autologous dendritic cells dendritic-cell-peptide immunization prostate-specific antigen mature dendritic cells dendritic cells suitable related subjects article cancer immunology localized prostate cancer dendritic cell subsets author information authors full article pdf privacy choices/manage cookies outcome based staging immature myeloid cells recombinant human psa dendritic cell immunobiology dendritic cells prostate cancer patients b-cell lymphoma blood-derived cd8+ positive skin tests rt-pcr positive clinically localized adenocarcinoma author correspondence postbaseline blood tests immune response specific european economic area isolated postoperative rise low gleason score severe toxicities observed check access generate large quantities viral peptide antigens rare earth cryptates johns hopkins experience experimental adjuvant therapy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA
         description:This study was conducted in prostate cancer patients in biochemical relapse after radical prostatectomy, to assess the feasibility, safety, and immunogenicity of therapeutic vaccination with autologous dendritic cells (DCs) pulsed with human recombinant prostate-specific antigen (PSA) (Dendritophage-rPSA). Twenty-four patients with histologically proven prostate carcinoma and an isolated postoperative rise of serum PSA (>1 ng/ml to 10 ng/ml) after radical prostatectomy were included. The patients received nine administrations of PSA-loaded DCs by combined intravenous, subcutaneous, and intradermal routes over 21 weeks. Postbaseline blood tests were performed at months 1, 3, 6, 9, and 12 (PSA levels), at months 6 and 12 (circulating prostate cancer cells), at month 6 (anti-PSA IgG and IgM antibodies), and at up to eight time points before, during, and after immunization (PSA-specific T cells). Circulating prostate cancer cells detected in six patients at baseline were undetectable at 6 months and remained undetectable at 12 months. Eleven patients had a postbaseline transient PSA decrease on one to three occasions, predominantly occurring at month 1 (7 patients) or month 3 (2 patients). Maximum PSA decrease ranged from 6% to 39%. PSA decrease on at least one occasion was more frequent in patients with low Gleason score (p=0.016) at prostatectomy and with positive skin tests at study baseline (p=0.04). PSA-specific T cells were detected ex vivo by ELISpot for IFN-γ in 7 patients before vaccination and in 11 patients after vaccination. Of the latter 11 patients, 5 had detectable T cells both before and during the vaccination period, 4 only during the vaccination period, while 2 patients could for technical reasons not be assessed prevaccination. No induction of anti-PSA IgG or IgM antibodies was detected. There were no serious adverse events or otherwise severe toxicities observed during the trial. Immunization with Dendritophage-rPSA was feasible and safe in this cohort of patients. An immune response specific for PSA could be detected in some patients. A notable effect was the disappearance of circulating prostate cells in all patients who were RT-PCR positive before vaccination.
         datePublished:2004-02-04T00:00:00Z
         dateModified:2004-02-04T00:00:00Z
         pageStart:453
         pageEnd:460
         sameAs:https://doi.org/10.1007/s00262-003-0451-2
         keywords:
            Dendritic cells
            Prostate-specific antigen
            Circulating cancer cells
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0451-2/MediaObjects/s00262-003-0451-2flb1.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:53
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Benoît Barrou
               affiliation:
                     name:Hôpital la Pitié-Salpétrière
                     address:
                        name:Service d’Urologie, AP-HP, Hôpital la Pitié-Salpétrière, Paris, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Gérard Benoît
               affiliation:
                     name:Hôpital Kremlin-Bicêtre
                     address:
                        name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mahmoud Ouldkaci
               affiliation:
                     name:Hôpital Kremlin-Bicêtre
                     address:
                        name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Olivier Cussenot
               affiliation:
                     name:Hôpital Saint-Louis
                     address:
                        name:Service d’Urologie, AP-HP, Hôpital Saint-Louis, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Margarita Salcedo
               affiliation:
                     name:Immuno-Designed Molecules
                     address:
                        name:Immuno-Designed Molecules, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sudhanshu Agrawal
               affiliation:
                     name:Immuno-Designed Molecules
                     address:
                        name:Immuno-Designed Molecules, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Séverine Massicard
               affiliation:
                     name:Immuno-Designed Molecules
                     address:
                        name:Immuno-Designed Molecules, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nadège Bercovici
               affiliation:
                     name:Immuno-Designed Molecules
                     address:
                        name:Immuno-Designed Molecules, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mats L. Ericson
               affiliation:
                     name:Immuno-Designed Molecules
                     address:
                        name:Immuno-Designed Molecules, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nicolas Thiounn
               affiliation:
                     name:Hôpital Cochin
                     address:
                        name:Service d’Urologie, AP-HP, Hôpital Cochin, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA
      description:This study was conducted in prostate cancer patients in biochemical relapse after radical prostatectomy, to assess the feasibility, safety, and immunogenicity of therapeutic vaccination with autologous dendritic cells (DCs) pulsed with human recombinant prostate-specific antigen (PSA) (Dendritophage-rPSA). Twenty-four patients with histologically proven prostate carcinoma and an isolated postoperative rise of serum PSA (>1 ng/ml to 10 ng/ml) after radical prostatectomy were included. The patients received nine administrations of PSA-loaded DCs by combined intravenous, subcutaneous, and intradermal routes over 21 weeks. Postbaseline blood tests were performed at months 1, 3, 6, 9, and 12 (PSA levels), at months 6 and 12 (circulating prostate cancer cells), at month 6 (anti-PSA IgG and IgM antibodies), and at up to eight time points before, during, and after immunization (PSA-specific T cells). Circulating prostate cancer cells detected in six patients at baseline were undetectable at 6 months and remained undetectable at 12 months. Eleven patients had a postbaseline transient PSA decrease on one to three occasions, predominantly occurring at month 1 (7 patients) or month 3 (2 patients). Maximum PSA decrease ranged from 6% to 39%. PSA decrease on at least one occasion was more frequent in patients with low Gleason score (p=0.016) at prostatectomy and with positive skin tests at study baseline (p=0.04). PSA-specific T cells were detected ex vivo by ELISpot for IFN-γ in 7 patients before vaccination and in 11 patients after vaccination. Of the latter 11 patients, 5 had detectable T cells both before and during the vaccination period, 4 only during the vaccination period, while 2 patients could for technical reasons not be assessed prevaccination. No induction of anti-PSA IgG or IgM antibodies was detected. There were no serious adverse events or otherwise severe toxicities observed during the trial. Immunization with Dendritophage-rPSA was feasible and safe in this cohort of patients. An immune response specific for PSA could be detected in some patients. A notable effect was the disappearance of circulating prostate cells in all patients who were RT-PCR positive before vaccination.
      datePublished:2004-02-04T00:00:00Z
      dateModified:2004-02-04T00:00:00Z
      pageStart:453
      pageEnd:460
      sameAs:https://doi.org/10.1007/s00262-003-0451-2
      keywords:
         Dendritic cells
         Prostate-specific antigen
         Circulating cancer cells
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0451-2/MediaObjects/s00262-003-0451-2flb1.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:53
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Benoît Barrou
            affiliation:
                  name:Hôpital la Pitié-Salpétrière
                  address:
                     name:Service d’Urologie, AP-HP, Hôpital la Pitié-Salpétrière, Paris, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Gérard Benoît
            affiliation:
                  name:Hôpital Kremlin-Bicêtre
                  address:
                     name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mahmoud Ouldkaci
            affiliation:
                  name:Hôpital Kremlin-Bicêtre
                  address:
                     name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Olivier Cussenot
            affiliation:
                  name:Hôpital Saint-Louis
                  address:
                     name:Service d’Urologie, AP-HP, Hôpital Saint-Louis, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Margarita Salcedo
            affiliation:
                  name:Immuno-Designed Molecules
                  address:
                     name:Immuno-Designed Molecules, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sudhanshu Agrawal
            affiliation:
                  name:Immuno-Designed Molecules
                  address:
                     name:Immuno-Designed Molecules, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Séverine Massicard
            affiliation:
                  name:Immuno-Designed Molecules
                  address:
                     name:Immuno-Designed Molecules, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nadège Bercovici
            affiliation:
                  name:Immuno-Designed Molecules
                  address:
                     name:Immuno-Designed Molecules, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mats L. Ericson
            affiliation:
                  name:Immuno-Designed Molecules
                  address:
                     name:Immuno-Designed Molecules, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nicolas Thiounn
            affiliation:
                  name:Hôpital Cochin
                  address:
                     name:Service d’Urologie, AP-HP, Hôpital Cochin, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:53
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hôpital la Pitié-Salpétrière
      address:
         name:Service d’Urologie, AP-HP, Hôpital la Pitié-Salpétrière, Paris, France
         type:PostalAddress
      name:Hôpital Kremlin-Bicêtre
      address:
         name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
         type:PostalAddress
      name:Hôpital Kremlin-Bicêtre
      address:
         name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
         type:PostalAddress
      name:Hôpital Saint-Louis
      address:
         name:Service d’Urologie, AP-HP, Hôpital Saint-Louis, Paris, France
         type:PostalAddress
      name:Immuno-Designed Molecules
      address:
         name:Immuno-Designed Molecules, Paris, France
         type:PostalAddress
      name:Immuno-Designed Molecules
      address:
         name:Immuno-Designed Molecules, Paris, France
         type:PostalAddress
      name:Immuno-Designed Molecules
      address:
         name:Immuno-Designed Molecules, Paris, France
         type:PostalAddress
      name:Immuno-Designed Molecules
      address:
         name:Immuno-Designed Molecules, Paris, France
         type:PostalAddress
      name:Immuno-Designed Molecules
      address:
         name:Immuno-Designed Molecules, Paris, France
         type:PostalAddress
      name:Hôpital Cochin
      address:
         name:Service d’Urologie, AP-HP, Hôpital Cochin, Paris, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Benoît Barrou
      affiliation:
            name:Hôpital la Pitié-Salpétrière
            address:
               name:Service d’Urologie, AP-HP, Hôpital la Pitié-Salpétrière, Paris, France
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Gérard Benoît
      affiliation:
            name:Hôpital Kremlin-Bicêtre
            address:
               name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
      name:Mahmoud Ouldkaci
      affiliation:
            name:Hôpital Kremlin-Bicêtre
            address:
               name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
               type:PostalAddress
            type:Organization
      name:Olivier Cussenot
      affiliation:
            name:Hôpital Saint-Louis
            address:
               name:Service d’Urologie, AP-HP, Hôpital Saint-Louis, Paris, France
               type:PostalAddress
            type:Organization
      name:Margarita Salcedo
      affiliation:
            name:Immuno-Designed Molecules
            address:
               name:Immuno-Designed Molecules, Paris, France
               type:PostalAddress
            type:Organization
      name:Sudhanshu Agrawal
      affiliation:
            name:Immuno-Designed Molecules
            address:
               name:Immuno-Designed Molecules, Paris, France
               type:PostalAddress
            type:Organization
      name:Séverine Massicard
      affiliation:
            name:Immuno-Designed Molecules
            address:
               name:Immuno-Designed Molecules, Paris, France
               type:PostalAddress
            type:Organization
      name:Nadège Bercovici
      affiliation:
            name:Immuno-Designed Molecules
            address:
               name:Immuno-Designed Molecules, Paris, France
               type:PostalAddress
            type:Organization
      name:Mats L. Ericson
      affiliation:
            name:Immuno-Designed Molecules
            address:
               name:Immuno-Designed Molecules, Paris, France
               type:PostalAddress
            type:Organization
      name:Nicolas Thiounn
      affiliation:
            name:Hôpital Cochin
            address:
               name:Service d’Urologie, AP-HP, Hôpital Cochin, Paris, France
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Service d’Urologie, AP-HP, Hôpital la Pitié-Salpétrière, Paris, France
      name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
      name:Service d’Urologie, AP-HP, Hôpital Kremlin-Bicêtre, Paris, France
      name:Service d’Urologie, AP-HP, Hôpital Saint-Louis, Paris, France
      name:Immuno-Designed Molecules, Paris, France
      name:Immuno-Designed Molecules, Paris, France
      name:Immuno-Designed Molecules, Paris, France
      name:Immuno-Designed Molecules, Paris, France
      name:Immuno-Designed Molecules, Paris, France
      name:Service d’Urologie, AP-HP, Hôpital Cochin, Paris, France
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(124)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.17s.

LINK . SPRINGER . COM {}